This post is from a low-reputation account and contains an unverified outbound link. Be cautious before clicking external links.
Bevacizumab has transformed cancer treatment by targeting the tumour’s blood supply to inhibit its growth. From metastatic colorectal cancer to glioblastoma multiforme and cervical cancer, its versatility makes it an essential tool for oncologists. While its use in breast cancer is still debated, its impact on survival rates and disease progression is significant.